LivaNova PLC (NASDAQ:LIVN) is one of the Best Undervalued UK Stocks to Buy According to Analysts. On June 6, Jefferies analyst Matthew Taylor maintained a Buy rating on LivaNova PLC (NASDAQ:LIVN) with a price target of $79.
The analyst highlighted the company’s strong growth potential driven by its solid product cycle. He noted the Essenz upgrade, which is expected to increase revenue by higher average selling prices as the replacement cycle advances. Moreover, Taylor also likes the company’s expansion in the oxygenator market. He believes that the increasing market share and production capacity give LivaNova PLC (NASDAQ:LIVN) a competitive edge over its peers.
A close-up of a medical device used for therapeutic solutions in a world-class hospital.
He also points out the company’s progress in Vagus Nerve Stimulation therapy for epilepsy, backed by strong long-term data. Taylor believes this strengthens its position in drug-resistant epilepsy treatment.
LivaNova PLC (NASDAQ:LIVN) is a global medical technology company that designs and manufactures devices for cardiac surgery and neuromodulation.
While we acknowledge the potential of LIVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
